Marty Hinz, MD

Speaker, 48th Annual International Orthomolecular Medicine Today Conference

Biography

Dr. Marty Hinz graduated from the University of Minnesota School of Medicine – Minneapolis, in 1983 and went on to complete a family practice residency in 1985. As the President of NeuroResearch Inc, Dr. Hinz is focused on the clinical applications of amino acids for the management of various neurological conditions. He is actively involved with educating physicians and other health care professionals on the topics of drug-induced nutrient depletion and optimizing treatment outcomes with nutritional intervention. The work of Dr. Hinz and his colleagues has resulted in numerous studies published in peer reviewed scientific journals.

Presentation Abstract

Optimizing Glutathione Interactions with Thiols and Centrally Acting Monoamines

Glutathione is the most common sulfur amino acid (thiol). The current science is not what is commonly believed by many. This presentation will discuss:

  • The management of glutathione’s ability to deplete serotonin and dopamine
  • The ability of L-dopa, 5-HTP, dopamine, and serotonin to deplete glutathione and the six other thiols
  • The role of homocysteine as the precursor of glutathione
  • The impact of vitamin B6 on homocysteine and glutathione concentrations
  • Glutathione’s interaction with the six other thiols
  • Glutathione’s interaction with 5-methyltetrahydrofolate reductase (5-MTHFR)
  • The use of n-acetylcysteine as a glutathione precursor

Publications

1. Hinz, M. Stein, A, Uncini T. The dual-gate lumen model of renal monoamine transport Neuropsychiatric Disease and Treatment. 2010, 6 387–392

2. Stein, A. Hinz, M. Uncini T. Amino acid responsive Crohn’s disease, a case study. Clinical and Experimental Gastroenterology. 2010:3 171–177

3. Hinz, M. Stein A. Uncini T. Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation Neuropsychiatric Disease and Treatment. 2011:7 31–38

4. Hinz, M. Stein, A. Uncini T. Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine Open Access Journal of Urology. 2011:3 19–24

5. Hinz, M. Stein, A. Uncini T. Amino acid management of Parkinson disease: A case study International Journal of General Medicine. 2011:4 1–10

6. Hinz, M. Stein, A. Uncini T. Validity of urinary monoamine assay sales under the“spot baseline urinary neurotransmitter testing marketing model” International Journal of Nephrology and Renovascular Disease. 2011:4 101–113

7. Hinz, M. Stein, A. Uncini T. APRESS: apical regulatory super system, serotonin, and dopamine interaction Neuropsychiatric Disease and Treatment. 2011:7 1–7

8. Hinz, M. Depression In: Kohlstadt I. editor. Food and Nutrients in Disease Management. CRC Press; 2009, 465-481

9. Trachte, G. Uncini, T. Hinz, M, 2009 Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population Neuropsychiatric Disease and Treatment. 2009, 5:227–235

10. Hinz, M. Stein, A, Trachte, G, Uncini T. Neurotransmitter testing of the urine; a comprehensive analysis. Open Access Journal of Urology. 2010:2 177–183

11. Hinz, M. Stein, A. Uncini T. A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole, NeuroPsychiatric Disease and Treatment Neuropsychiatric Disease and Treatment. 2010, 6:741–747

12. Hinz, M. Stein, A. Uncini T. Monoamine depletion by reuptake inhibitors. International Drug, Healthcare and Patient Safety. 2011:3 69–77

13. Hinz, M. Stein, A. Uncini T. The discrediting of the monoamine hypothesis. International Journal of General Medicine International Journal of General Medicine. 2012:5 135–142

14. Hinz, M. Stein, A. Uncini T Relative nutritional deficiencies associated with centrally acting monoamines International Journal of General Medicine. 2012:5413–430

15. Hinz, M. Stein, A. Uncini T 5-HTP efficacy and contraindicationsNeuropsychiatric Disease and Treatment. 2012:8 323–328

16. Hinz, M. et. al. Administration of supplemental L-tyrosine with phenelzine: a clinical literature review, Clinical Pharmacology: Advances and Applications. 2014:6 107–110

17. Hinz, M. et. al. Management of L-dopa overdose in the competitive inhibition state, Drug, Healthcare and Patient Safety. 2014:6 93–99

18. Hinz, M. et. al. The Parkinson’s disease death rate: carbidopa and vitamin B6,Clinical Pharmacology: Advances and Applications. 2014:6 161–169

19. Hinz, M. et.al. Parkinson’s disease: carbidopa, nausea, and dyskinesia, Clinical Pharmacology: Advances and Applications. 2014:6 189–194

20. Hinz, M. et. al. Parkinson’s disease-associated melanin steal, Neuropsychiatric Disease and Treatment. 2014:10 2331–2337

21. Hinz, M. et. al. Parkinson’s disease managing reversible neurodegeneration, neuropsychiatric disease and treatment, submission pending, submitted October 17, 2015.